Anamorelin(Adlumiz)

In January 2021, anamorelin, a prescription drug targeting the ghrelin receptor GHS‑R1a, was approved for marketing in Japan and officially launched in April of the same year. Use it strictly as directed by a doctor.

Target

Ghrelin receptor GHS‑R1a

Mechanism of Action

Anamorelin exerts its pharmacological effects by activating the ghrelin receptor GHS‑R1a.

Activation of this receptor in the hypothalamus increases appetite, while in the pituitary gland it promotes growth hormone (GH) secretion.

GH secreted by the pituitary gland stimulates the liver to synthesize and release insulin‑like growth factor‑1 (IGF‑1), which in turn promotes muscle protein synthesis, leading to increased muscle mass and body weight.

Dosage and Administration

Route and frequency of administration for anamorelin:

Oral administration, once daily.

The dosage of anamorelin should be adjusted according to the patient’s actual condition. For specific dosing, consult a physician and strictly follow medical advice.

Recommended reading: Dosage and Administration of Anamorelin

Adverse Reactions

Common adverse reactions: nausea, diarrhea, abdominal pain, etc.

Serious adverse reactions: hyperglycemia and worsening of diabetes mellitus, inhibition of the cardiac conduction system, etc.

Reference article: Adverse Reactions of Anamorelin

Use in Special Populations

Pregnancy:

This product may be used only if the anticipated therapeutic benefit outweighs the potential risks.

Lactation:

A careful balance should be made between the therapeutic benefit and the importance of breastfeeding, to decide whether to continue breastfeeding or discontinue this product.

Given anamorelin’s high lipophilicity and weak basicity, it may be excreted into breast milk; careful evaluation is required.

Precautions

1. Regular monitoring of blood glucose, electrocardiogram (ECG), and liver function is required during treatment.

2. If chest pain, palpitations, or persistent vomiting occurs, discontinue the drug immediately and seek medical attention.

3. Concomitant use with CYP3A4 inhibitors (e.g., clarithromycin) may increase plasma concentrations of anamorelin, requiring dosage adjustment.

fromJP,2023.02